What Your Wearable Knows That Your Doctor Ignores: Weekly Livestream W/ Brooks Leitner

Key Takeaways

• VO2 max predicts mortality better than cholesterol, blood pressure
• Longevity platforms rarely include functional metrics like VO2 max
• Apple Watch, Garmin, Fitbit already estimate VO2 max for users
• Live stream April 17 features Dr. Brooks Leitner on healthspan
• Biological age scores miss functional capacity, limiting healthspan insights

Pulse Analysis

VO2 max, the maximal oxygen uptake during intense exercise, has emerged as a gold‑standard indicator of cardiovascular fitness. Decades of epidemiological research, including recent analyses of the Framingham Heart Study, show that higher VO2 max levels correlate with lower all‑cause mortality, often outpacing traditional risk factors such as LDL cholesterol, hypertension, or diabetes. Because it reflects the integrated performance of the heart, lungs, and muscles, VO2 max offers a real‑time snapshot of functional health that static lab tests cannot capture.

The longevity industry has built a multi‑billion‑dollar ecosystem around biological‑age algorithms, genomic panels, and full‑body imaging, yet most platforms still overlook functional metrics. This omission creates a strategic gap: investors and consumers are increasingly demanding data that predicts not just how long they will live, but how well they will function in later years. Wearable manufacturers have quietly filled part of this void—Apple Watch, Garmin, and Fitbit now calculate VO2 max using heart‑rate and motion sensors, delivering actionable insights directly to users’ wrists. Companies that integrate these wearable‑derived scores with their existing diagnostic dashboards can offer a more holistic health‑span narrative, potentially unlocking new revenue streams and boosting user engagement.

The upcoming live stream with Dr. Brooks Leitner, a former NIH metabolism researcher and venture investor, aims to spotlight this missing piece. By framing VO2 max as a cornerstone of health‑span planning, the conversation could accelerate product roadmaps for startups and established health‑tech firms alike. For investors, the session signals a shift toward functional‑performance data as a differentiator in a crowded market. For consumers, it provides a concrete metric to track and improve, turning the abstract goal of longevity into a measurable, everyday pursuit.